Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of multiple myeloma (a type of blood cancer)
- People who received their first dose of teclistamab on or before 31 December 2022 (REALiTEC Cohort 1), OR between 1 January 2023 and 31 December 2024 (REALiTEC Cohort 2), OR between 1 January 2025 and 31 December 2025 (REALiTEC Cohort 3), regardless of how long treatment lasted
- People who received their first dose of talquetamab on or before 31 December 2023, regardless of how long treatment lasted (REALiTAL Cohort)
- People who received both teclistamab and talquetamab, as inclusion in both the REALiTEC and REALiTAL cohorts may be possible
- People who received at least one dose of teclistamab or talquetamab
- People who have signed a consent form, or where a consent waiver applies for deceased patients depending on the country or site requirements
Who may not be able to join:
- People whose teclistamab was received as part of another interventional clinical trial are not eligible for the REALiTEC cohorts
- People whose talquetamab was received as part of another interventional clinical trial are not eligible for the REALiTAL cohort
- People who received teclistamab through a Janssen pre-approval access program are not eligible for REALiTEC Cohort 2 or REALiTEC Cohort 3
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen-Cilag Limited Clinical Trial, Janssen-Cilag Limited
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Describe Baseline Characteristics of Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who Received Teclistamab/ Talquetamab Outside of Clinical Trials; Overall Response Rate (ORR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to First Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Best Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Duration of Response (DOR) in Participants with RRMM who Received Teclistamab/Talquetamab...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.